{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:23:29Z","timestamp":1760189009031},"reference-count":42,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2008,10,21]],"date-time":"2008-10-21T00:00:00Z","timestamp":1224547200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2008,12]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>The dual c\u2010abl\/Src kinase inhibitor, dasatinib, utilized to treat chronic myeloid leukaemia (CML) when used at clinically attainable sublethal concentrations, synergistically sensitized primary chronic lymphocytic leukaemia (CLL) lymphocytes to chlorambucil and fludarabine. In contrast, dasatinib alone demonstrated toxicity to CLL lymphocytes at concentrations that are generally not clinically attainable. Dasatinib resistance and poorer dasatinib\u2010mediated sensitization to chlorambucil and fludarabine was associated with higher expression of c\u2010abl protein levels. In contrast, chlorambucil and fludarabine resistance correlated with basal p53 protein levels. Moreover, Western blot analysis after <jats:italic>in vitro<\/jats:italic> treatment of primary CLL lymphocytes with dasatinib, chlorambucil and\/or fludarabine, showed that dasatinib: (i) inhibited c\u2010abl function (e.g. downregulation of c\u2010abl protein levels and decreased the phosphorylation of a c\u2010abl downstream target, Dok2), (ii) decreased chlorambucil\/fludarabine induced accumulation of p53 protein levels, (iii) altered the response to chlorambucil\/fludarabine induced DNA\u2010damage as evidenced by an increase in chlorambucil\/fludarabine\u2010induced H2AX phosphorylation, and (iv) accentuated the c\u2010abl downregulation induced by chlorambucil\/fludarabine. Our results suggest that dasatinib in combination with chlorambucil or fludarabine may improve the therapy of CLL.<\/jats:p>","DOI":"10.1111\/j.1365-2141.2008.07418.x","type":"journal-article","created":{"date-parts":[[2008,11,10]],"date-time":"2008-11-10T00:57:19Z","timestamp":1226278639000},"page":"698-706","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["Dasatinib sensitizes primary chronic lymphocytic leukaemia lymphocytes to chlorambucil and fludarabine <i>in vitro<\/i>"],"prefix":"10.1111","volume":"143","author":[{"given":"Lilian","family":"Amrein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiffany A.","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristiano","family":"Ferrario","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Spencer B.","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence","family":"Panasci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raquel","family":"Aloyz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,11,11]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403247"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.106.118356"},{"issue":"1","key":"e_1_2_6_4_1","first-page":"S103","article-title":"Chlorambucil induced apoptosis in chronic lymphocytic leukemia (CLL) and its relationship to clinical efficacy","volume":"8","author":"Begleiter A.","year":"1994","journal-title":"Leukemia"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428199609054821"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-2952(02)00954-1"},{"key":"e_1_2_6_7_1","first-page":"4558","article-title":"Re: W. R. Greco et\u00a0al, Application of a new approach for the quantitation of drug synergism to the combination of cis\u2010diamminedichloroplatinum and 1\u2010beta\u2010D\u2010arabinofuranosylcytosine. Cancer Research, 50, 5318\u20135327, 1990","volume":"52","author":"Berenbaum M.C.","year":"1992","journal-title":"Cancer Research"},{"key":"e_1_2_6_8_1","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1182\/blood.V87.7.2615.bloodjournal8772615","article-title":"B\u2010chronic lymphocytic leukemia: a malignancy of anti\u2010self B cells","volume":"87","author":"Caligaris\u2010Cappio F.","year":"1996","journal-title":"Blood"},{"key":"e_1_2_6_9_1","first-page":"1789","article-title":"Potentiation of chlorambucil cytotoxicity in B\u2010cell chronic lymphocytic leukemia by inhibition of DNA\u2010dependent protein kinase activity using wortmannin","volume":"58","author":"Christodoulopoulos G.","year":"1998","journal-title":"Cancer Research"},{"key":"e_1_2_6_10_1","first-page":"2178","article-title":"Chlorambucil induction of HsRad51 in B\u2010cell chronic lymphocytic leukemia","volume":"5","author":"Christodoulopoulos G.","year":"1999","journal-title":"Clinical Cancer Research"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI200522094"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbi.2005.03.002"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-07-2888"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2007.02.021"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI3009"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2008.68"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-4658.2005.04741.x"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.164.4.2200"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-03-011759"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.4161\/cc.3.9.1126"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910420410"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0268-960X(97)90007-2"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.03149.x"},{"key":"e_1_2_6_24_1","first-page":"51","article-title":"Expression and location of pro\u2010apoptotic Bcl\u20102 family protein BAD in normal human tissues and tumor cell lines","volume":"152","author":"Kitada S.","year":"1998","journal-title":"American Journal of Pathology"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cdd.4401925"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-3901"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.4161\/cc.6.5.3923"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-008-0699-5"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M301339200"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0b013e3281721ff6"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1210179"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2567.2005.02117.x"},{"key":"e_1_2_6_33_1","first-page":"454","article-title":"Chlorambucil drug resistance in chronic lymphocytic leukemia: the emerging role of DNA repair","volume":"7","author":"Panasci L.","year":"2001","journal-title":"Clinical Cancer Research"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1097\/00001813-200203000-00002"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-0753"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-09-3236"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-007-0048-6"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(91)90012-N"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1038\/cr.2007.111"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.21.17.5869-5878.2001"},{"key":"e_1_2_6_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(91)90011-M"},{"key":"e_1_2_6_42_1","article-title":"Dasatinib pharmacokinetics and exposure\u2010response (E\u2010R): Relationship to safety and efficacy in patients (pts) with chronic myeloid leukemia (CML)","volume":"26","author":"Wang X.","year":"2008","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_2_6_43_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.165.12.6872"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2141.2008.07418.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2141.2008.07418.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T05:33:03Z","timestamp":1695965583000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2141.2008.07418.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,11,11]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008,12]]}},"alternative-id":["10.1111\/j.1365-2141.2008.07418.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2141.2008.07418.x","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,11,11]]},"assertion":[{"value":"2008-11-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}